Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic cytomegalovirus-specific memory T cells
- Development stage
- Unknown
- Lead developer
- IDIVAL
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic cytomegalovirus-specific memory T cells are an adoptive cellular immunotherapy developed by the Instituto de Investigación Marqués de Valdecilla (IDIVAL) for the treatment and prevention of cytomegalovirus (CMV) infection in immunocompromised patients, particularly those undergoing hematopoietic stem cell transplantation (HSCT). These cells are typically isolated from healthy, CMV-seropositive donors and selected or expanded to target specific CMV antigens, most commonly the 65 kDa lower matrix phosphoprotein (pp65) and Immediate-early protein 1 (IE-1). Once infused into the patient, these memory T cells provide immediate cellular immunity against the virus, bypassing the patient's own compromised immune system to control viral replication and reduce the incidence of CMV-related disease and associated mortality.
- Other names
- CMV-specific T cellsCMV-specific cytotoxic T lymphocytesCMV-VSTsallogeneic CMV-specific T lymphocytesCMV-CTLs
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on allogeneic cytomegalovirus-specific memory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic cytomegalovirus-specific memory T cells.